REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

NCT04523428 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

CLL/SLL

Interventions

DRUG: Venetoclax/Acalabrutinib

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland